Synthesis, Experimental and Computational Evaluation of SERAAK1 as a 5-HT<sub>2A</sub> Receptor Ligand
Many drug discovery efforts have identified potentially promising molecules; however, a common limitation of these reports is the lack of further experimental confirmation of pharmacokinetic properties and behavioral effects of discovered compounds. In this study, we aim to address this limitation....
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/30/10/2165 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Many drug discovery efforts have identified potentially promising molecules; however, a common limitation of these reports is the lack of further experimental confirmation of pharmacokinetic properties and behavioral effects of discovered compounds. In this study, we aim to address this limitation. Therefore, we build on our previous virtual screening campaign by synthesizing, analyzing in silico, and evaluating experimentally the SERAAK1 compound, which was initially identified as a ligand for 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, and D<sub>2</sub> receptors. Through these investigations, we discovered that SERAAK1 binds to the orthosteric pocket of the 5-HT<sub>2A</sub> receptor in a similar mechanism to that known for marketed antipsychotic medications. Molecular dynamics simulations revealed that the SERAAK1 compound remains stable in the orthosteric binding pocket of the 5-HT<sub>2A</sub> receptor. The determination of the ADMET parameters indicated the directions for further optimization of the compounds. In vivo studies demonstrated the anxiolytic and antidepressant properties of the SERAAK1 compound. |
|---|---|
| ISSN: | 1420-3049 |